Related Experiment Video

Updated: Oct 1, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and

Stephanie Läer1, Thomas S Mir, Frederike Behn

  • 1Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Abteilung für Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. laeer@uke.uni-hamburg.de

American Heart Journal
|June 1, 2002
PubMed

Insights

Oral carvedilol shows clinical benefit in pediatric patients with congestive heart failure (CHF) unresponsive to standard treatments. Further research is needed to define optimal dosing strategies due to faster carvedilol elimination in children.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Congestive Heart Failure Management

Background:

  • Standard therapies for pediatric congestive heart failure (CHF) include digoxin, ACE inhibitors, and diuretics.
  • Some pediatric CHF patients do not respond adequately to these conventional treatments.
  • Evaluating alternative or adjunctive therapies is crucial for improving outcomes in refractory pediatric CHF.

Purpose of the Study:

  • To assess the clinical efficacy of oral carvedilol in pediatric patients with CHF who are refractory to standard medical management.
  • To determine the pharmacokinetic profile of carvedilol in this pediatric population.
  • To compare carvedilol's elimination half-life in pediatric CHF patients versus healthy adults.

Main Methods:

  • A prospective, open-label intervention trial was conducted.
  • Fifteen pediatric patients with CHF received oral carvedilol using a ramped dosing scheme.
  • Clinical parameters and carvedilol pharmacokinetics were evaluated over six months, with comparisons to healthy adult volunteers.

Main Results:

  • All 15 pediatric patients tolerated carvedilol and reached target doses.
  • Significant improvements were observed in ejection fraction (36% to 54%) and modified Ross Score (5±2 to 3±3) after six months.
  • Carvedilol's elimination half-life was approximately 50% shorter in pediatric CHF patients (2.9 hours) compared to healthy adults (5.2 hours).

Conclusions:

  • Oral carvedilol may be beneficial for pediatric patients with CHF who do not respond to standard therapies.
  • The accelerated elimination of carvedilol in children necessitates further investigation into optimal dosing strategies for this population.
  • Carvedilol represents a potential treatment option for refractory pediatric congestive heart failure, pending further pharmacokinetic studies.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...